BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meeker AS, Herink MC, Haxby DG, Hartung DM. The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis. Syst Rev 2015;4:21. [PMID: 25874839 DOI: 10.1186/s13643-015-0001-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Berk A, Yılmaz İ, Abacıoğlu N, Kaymaz MB, Karaaslan MG, Kuyumcu Savan E. Antidepressant effect of Gentiana olivieri Griseb. in male rats exposed to chronic mild stress. Libyan J Med 2020;15:1725991. [PMID: 32048914 DOI: 10.1080/19932820.2020.1725991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li G, Yang J, Wang X, Zhou C, Zheng X, Lin W. Effects of EGCG on depression-related behavior and serotonin concentration in a rat model of chronic unpredictable mild stress. Food Funct 2020;11:8780-7. [DOI: 10.1039/d0fo00524j] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology 2016;26:979-93. [DOI: 10.1016/j.euroneuro.2016.03.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 54] [Article Influence: 13.8] [Reference Citation Analysis]
4 Deardorff WJ, Grossberg GT. The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Curr Geri Rep 2015;4:301-11. [DOI: 10.1007/s13670-015-0140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Zuena AR, Maftei D, Alemà GS, Dal Moro F, Lattanzi R, Casolini P, Nicoletti F. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol Pain 2018;14:1744806918808987. [PMID: 30289053 DOI: 10.1177/1744806918808987] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
6 Nomikos GG, Tomori D, Zhong W, Affinito J, Palo W. Efficacy, safety, and tolerability of vortioxetine for the treatment of major depressive disorder in patients aged 55 years or older. CNS Spectr 2017;22:348-62. [PMID: 27869048 DOI: 10.1017/S1092852916000626] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.2] [Reference Citation Analysis]
7 Maletic V, Eramo A, Gwin K, Offord SJ, Duffy RA. The Role of Norepinephrine and Its α-Adrenergic Receptors in the Pathophysiology and Treatment of Major Depressive Disorder and Schizophrenia: A Systematic Review. Front Psychiatry 2017;8:42. [PMID: 28367128 DOI: 10.3389/fpsyt.2017.00042] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
8 Orsolini L, Tomasetti C, Valchera A, Iasevoli F, Buonaguro EF, Vellante F, Fornaro M, Fiengo A, Mazza M, Vecchiotti R, Perna G, de Bartolomeis A, Martinotti G, Di Giannantonio M, De Berardis D. New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. Expert Rev Neurother 2016;16:483-95. [PMID: 27050932 DOI: 10.1586/14737175.2016.1173545] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
9 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
10 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
11 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
12 Siddiqui F, Barbateskovic M, Juul S, Katakam KK, Munkholm K, Gluud C, Jakobsen JC. Duloxetine versus 'active' placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Syst Rev 2021;10:171. [PMID: 34108032 DOI: 10.1186/s13643-021-01722-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 He H, Wang W, Lyu J, Zheng J, Guo L, An X, Fan Y, Ma X. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis. Journal of Psychiatric Research 2018;96:247-59. [DOI: 10.1016/j.jpsychires.2017.10.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
14 Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. Psychiatry Clin Neurosci 2020;74:140-8. [PMID: 31725942 DOI: 10.1111/pcn.12956] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Kato T, Furukawa TA, Mantani A, Kurata K, Kubouchi H, Hirota S, Sato H, Sugishita K, Chino B, Itoh K, Ikeda Y, Shinagawa Y, Kondo M, Okamoto Y, Fujita H, Suga M, Yasumoto S, Tsujino N, Inoue T, Fujise N, Akechi T, Yamada M, Shimodera S, Watanabe N, Inagaki M, Miki K, Ogawa Y, Takeshima N, Hayasaka Y, Tajika A, Shinohara K, Yonemoto N, Tanaka S, Zhou Q, Guyatt GH; SUN☺D Investigators. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med 2018;16:103. [PMID: 29991347 DOI: 10.1186/s12916-018-1096-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
16 Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Hum Psychopharmacol 2018;33. [PMID: 29327372 DOI: 10.1002/hup.2646] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Chin CN, Zain A, Hemrungrojn S, Ung EK, Kwansanit P, Au Yong KC, Chong MSW, Inpa C, Yen TH, Yeoh BBD, Tay LK, Bernardo C, Lim LC, Yap CH, Fones C, Nayak A, Nelleman L. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin 2018;34:1975-84. [PMID: 29768955 DOI: 10.1080/03007995.2018.1477746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord 2016;190:357-61. [PMID: 26546771 DOI: 10.1016/j.jad.2015.10.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, de Carvalho PMG, de Carvalho AAV, Oesterreich SA. Molecular aspects of depression: A review from neurobiology to treatment. Eur J Pharmacol 2019;851:99-121. [PMID: 30776369 DOI: 10.1016/j.ejphar.2019.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
20 Cosgrove L, Vannoy S, Mintzes B, Shaughnessy AF. Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. Accountability in Research 2016;23:257-79. [DOI: 10.1080/08989621.2016.1153971] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]